OBSIDIAN THERAPEUTICS

obsidian-therapeutics-logo

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

#SimilarOrganizations #People #Financial #Website #More

OBSIDIAN THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2015-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.obsidiantx.com

Total Employee:
51+

Status:
Active

Contact:
(781) 806-6245

Email Addresses:
[email protected]

Total Funding:
164.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box Amazon


Similar Organizations

ankyra-logo

Ankyra

Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.

aratana-therapeutics-logo

Aratana Therapeutics

Aratana Therapeutics develops innovative therapies for the animal health industry.

bwell-connected-health-logo

b.well Connected Health

b.well Connected Health provides an integrated solution for consumer engagement, holistic health management, and cost containment.

carerx-logo

CareRx

CareRx is a provider of pharmacy services to seniors communities.

century-therapeutics-logo

Century Therapeutics

Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.

cybin-logo

Cybin

Cybin is a life sciences company dedicated in advancing psychedelic therapeutics with the goal of transforming mental healthcare.

denteric-logo

Denteric

Denteric is developing a vaccine based on research conducted at the University of Melbourne.

dracen-pharmaceuticals-logo

Dracen Pharmaceuticals

Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.

dyne-therapeutics-logo

Dyne Therapeutics

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

eip-pharma-logo

EIP Pharma

EIP Pharma Provides Healthcare Services.

everest-medicines-logo

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.

genomic-prediction-logo

Genomic Prediction

Genomic Prediction provides advanced genetic testing for IVF.

icosavax-logo

Icosavax

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

jaguar-health-logo

Jaguar Health

Jaguar Health brings naturally derived important health solutions to all animals of the world, as proprietary.

kalderos-logo

Kalderos

Kalderos provides a SaaS based drug discount management solution, which identifies, checks, and resolves non-compliance.

neukio-biotherapeutics-logo

Neukio Biotherapeutics

Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.

nivien-therapeutics-logo

Nivien Therapeutics

Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.

pyxis-oncology-logo

Pyxis Oncology

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.

sante-basque-developpement-logo

Sante Basque Developpement

Sante Basque Developpement is owns and operates mental health hospitals.

syndesi-therapeutics-logo

Syndesi Therapeutics

Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.

tiburio-therapeutics-logo

Tiburio Therapeutics

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.

tune-therapeutics-logo

Tune Therapeutics

Tune Therapeutics is an epigenetic programming platform for the treatment of disease.

vico-therapeutics-logo

Vico Therapeutics

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

westlake-therapeutics-logo

Westlake Therapeutics

The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.

zucara-therapeutics-logo

Zucara Therapeutics

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.


Current Advisors List

cariad-chester_image

Cariad Chester Board Member @ Obsidian Therapeutics
Board_member

Current Employees Featured

michael-gilman_image

Michael Gilman
Michael Gilman Founder & CEO @ Obsidian Therapeutics
Founder & CEO

steve-shamah_image

Steve Shamah
Steve Shamah Senior Vice President & Head of Research @ Obsidian Therapeutics
Senior Vice President & Head of Research
2016-09-01

jan-ter-meulen_image

Jan Ter Meulen
Jan Ter Meulen CSO @ Obsidian Therapeutics
CSO

paul-wotton_image

Paul Wotton
Paul Wotton CEO @ Obsidian Therapeutics
CEO

parnian-zia-amirhosseini_image

Parnian Zia-Amirhosseini
Parnian Zia-Amirhosseini VP and Head of Regulatory Affairs & Quality Assurance @ Obsidian Therapeutics
VP and Head of Regulatory Affairs & Quality Assurance

catherine-stehman-breen_image

Catherine Stehman-Breen
Catherine Stehman-Breen CDO @ Obsidian Therapeutics
CDO

karen-brown_image

Karen Brown
Karen Brown SVP of Intellectual Property and Legal Affairs @ Obsidian Therapeutics
SVP of Intellectual Property and Legal Affairs

kirsten-kester_image

Kirsten Kester
Kirsten Kester Senior Vice President, Business Development @ Obsidian Therapeutics
Senior Vice President, Business Development
2022-01-01

ryan-daws_image

Ryan Daws
Ryan Daws Chief Financial Officer @ Obsidian Therapeutics
Chief Financial Officer
2019-01-01

shyam-subramanian_image

Shyam Subramanian
Shyam Subramanian SVP of Technical Operations and COE @ Obsidian Therapeutics
SVP of Technical Operations and COE

Founder


michael-gilman_image

Michael Gilman

steve-shamah_image

Steve Shamah

tariq-kassum_image

Tariq Kassum

Investors List

the-column-group_image

The Column Group

The Column Group investment in Series B - Obsidian Therapeutics

vertex-ventures-hc_image

Vertex Ventures HC

Vertex Ventures HC investment in Series B - Obsidian Therapeutics

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - Obsidian Therapeutics

amgen-ventures_image

Amgen Ventures

Amgen Ventures investment in Series B - Obsidian Therapeutics

bristol-myers-squibb_image

Bristol Myers Squibb

Bristol Myers Squibb investment in Series B - Obsidian Therapeutics

logos-capital_image

Logos Capital

Logos Capital investment in Series B - Obsidian Therapeutics

atlas-venture_image

Atlas Venture

Atlas Venture investment in Series B - Obsidian Therapeutics

deep-track-capital_image

Deep Track Capital

Deep Track Capital investment in Series B - Obsidian Therapeutics

samsara-biocapital_image

Samsara BioCapital

Samsara BioCapital investment in Series B - Obsidian Therapeutics

surveyor-capital_image

Surveyor Capital

Surveyor Capital investment in Series B - Obsidian Therapeutics

Official Site Inspections

http://www.obsidiantx.com Semrush global rank: 3.54 M Semrush visits lastest month: 4.15 K

  • Host name: 2.198.243.35.bc.googleusercontent.com
  • IP address: 35.243.198.2
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...

More informations about "Obsidian Therapeutics"

Pioneering engineered cell and gene therapies - Obsidian โ€ฆ

Dr. Pao served as Chief Development Officer and Executive Vice President for Pfizer, where he was a member of the Executive Leadership Team and led the Global Product Development โ€ฆSee details»

Obsidian Therapeutics - Crunchbase Company Profile โ€ฆ

Contact Email [email protected] Phone Number (781) 806-6245 Obsidian Therapeutics is a developer of a next-generation cell and gene therapies โ€ฆSee details»

Obsidian Therapeutics Announces Appointment of William Pao, โ€ฆ

CAMBRIDGE, Mass., June 4, 2024 โ€“ Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of โ€ฆSee details»

Obsidian Therapeutics Company Overview, Contact Details

Apr 3, 2024 Dec 11, 2023 | obsidiantx.com. Obsidian Therapeutics, Inc. launched OBX-115 on Jul 1st '22. In July 2022, CTMC and Obsidian Therapeutics announced FDA clearance of the โ€ฆSee details»

Obsidian Therapeutics - LinkedIn

Obsidian Therapeutics Biotechnology Research Cambridge, MA 9,966 followers At Obsidian, our vision is pioneering engineered cell & gene therapies to deliver transformative outcomes for patients.See details»

Obsidian Therapeutics - VentureRadar

"Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing โ€ฆSee details»

MD Anderson and Obsidian Therapeutics announce FDA clearance โ€ฆ

Information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter. About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of โ€ฆSee details»

Obsidian Therapeutics, Inc. (Obsidian Therapeutics, Inc.) - ่ฏ็‰ฉ็ฎก โ€ฆ

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that โ€ฆSee details»

News - Obsidian Therapeutics

Based upon the work of Professor Thomas Wandless, a leading researcher in chemical and systems biology, Obsidian was founded in 2015 and is funded by a strong syndicate of venture investors. The company is headquartered in โ€ฆSee details»

Obsidian Therapeutics - Overview, News & Similar companies

Obsidian Therapeutics contact info: Phone number: (781) 806-6245 Website: www.obsidiantx.com What does Obsidian Therapeutics do? Obsidian Therapeutics, Inc. is a โ€ฆSee details»

Vertex and Obsidian Therapeutics Establish Collaboration to โ€ฆ

Apr 22, 2021 For more information, please visit www.obsidiantx.com. About Vertex Pharmaceuticals. Vertex is a global biotechnology company that invests in scientific innovation โ€ฆSee details»

MD Anderson and Obsidian Therapeutics announce FDA โ€ฆ

Jul 21, 2022 For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter. Obsidian Therapeutics Media Contact: Erica Fiorini, Ph.D., or Liz Philips Russo โ€ฆSee details»

Obsidian Therapeutics Announces Positive Interim Top-Line

Obsidian Therapeutics, Inc. is a clinicalstage- biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.See details»

Vertex and Obsidian Therapeutics Establish Collaboration to โ€ฆ

Obsidianโ€™s proprietary cytoDRiVE® technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of โ€ฆSee details»

Recommended Stories - Yahoo Finance

CAMBRIDGE, Mass., December 12, 2023--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, announced today โ€ฆSee details»

Obsidian Therapeutics to Present Clinical Data from OBX-115, its ...

CAMBRIDGE, Mass., April 24, 2024--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, โ€ฆSee details»

Obsidian Therapeutics to Present at Upcoming Investor Conferences

Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit โ€ฆSee details»

Working at Obsidian Therapeutics - Glassdoor

Obsidiantx.com. Obsidian Therapeutics Announces Closing of $115 Million Series B Financing. Like. 0. See all company updates. Work at Obsidian Therapeutics? Share your experiences. โ€ฆSee details»

Obsidian Therapeutics to Present Preclinical Data Supporting OBX โ€ฆ

Preclinical data confirm the successful generation of OBX-115 using core needle biopsy tumor tissue procurement in NSCLC Additional posters showcase the ability of cytoDRiVE regulation โ€ฆSee details»

linkstock.net © 2022. All rights reserved